Is hyaluronidase safe? Understanding the risks of dissolving filler

Hyaluronidase is an enzyme, a substance that helps break down other molecules. In this setting, its action on hyaluronic acid is the reason it may be considered. Establishing what the filler contains therefore comes before deciding whether dissolving it is appropriate.

Facial fillers can contain different materials. An approach that works on one material cannot automatically be applied to another. The FDA also explains that reducing or removing filler can be difficult and may involve additional procedures, depending on the material and the problem.

If the original product is unknown, that uncertainty needs to be included in the assessment. A treatment record or product identification can be helpful when available.

Local discomfort, swelling and bruising should be discussed before an injection. Hyaluronidase can also cause an allergic reaction, which may be serious. A history of allergies or reactions to previous treatments is relevant information for the clinician.

There is also uncertainty about the cosmetic outcome. Reducing filler volume may change the contour in a way that differs from the intended result. The consultation should establish exactly which area is causing concern, what change is being sought and the limits of a correction.

The Spanish medicines agency, AEMPS, has issued information on the correct use of hyaluronidase. Its use belongs in a healthcare setting with an appropriate product. Knowing the identity and source of the substance being administered is part of procedural safety.

The aim may be to reduce unwanted volume or address a filler-related problem. Whether that aim can be achieved depends on the findings at assessment. Dissolving filler cannot guarantee an exact return to the appearance before treatment.

The FDA notes that procedures intended to reduce or remove filler carry risks of their own. This deserves a separate discussion, even if the original treatment was described as reversible.

Before proceeding, it helps to agree what improvement is realistic, which concerns might remain and how the response will be reviewed. That is more useful than relying on a general expectation that everything will go back to how it was.

A simple timeline can help distinguish what was noticed immediately after treatment from changes that developed later. Useful information includes:

• The product name or treatment record, if available.
• The approximate treatment date and the areas injected.
• Any later treatment in the same area, including previous hyaluronidase.
• Symptoms and how they have changed.
• Medical history, allergies and current medication for the clinician to review.

Missing information can simply be identified as unknown. Separating established details from uncertainties supports a more informed decision.

Following filler treatment, unusual or severe pain, striking changes in skin colour or visual symptoms require immediate medical attention. The FDA includes these symptoms in its filler safety warnings. They should be assessed as a possible complication rather than left for a routine aesthetic appointment.

After any injection, breathing difficulty, swelling of the tongue or throat, or collapse also requires emergency care because of the possibility of a serious reaction.

The consultation should explain what problem is being treated, why dissolving is proposed and what alternatives exist. Follow-up arrangements and symptoms that require immediate attention should also be clear.

An individual assessment brings these points together. Understanding the expected benefit, risks and limitations makes it possible to decide with a specific goal, rather than treating dissolvability as a guarantee that a filler result can be corrected.